Peptides DB
Research-centric peptide and protocol reference hub

Dulaglutide record · updated 6h ago

Metabolic & appetiteInflammation & immuneGrade A · human clinicalResearch use only
All 20 studiesJump to the evidenceCompare
What is Dulaglutide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Dulaglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 89 registered trials. It describes the research record, not a recommendation.

Identity
NameDulaglutide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026
Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~5 days
Time to peak24–48 hours
DurationOnce weekly
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 21, 2026. How this works →
Research stats
Total studies20
Human / animal / cellular8 / 1 / 1
Highest trial phasePhase 4
Years covered2023–2026
Latest study1d ago
Publication history
20232026
Research funding
17 NIH projects · $7.6M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports1,534
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

20 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
Finding8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.
Human2026Full text read0.80
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
FindingGLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)
Human2024Full text read0.80
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
FindingETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59
Human2026Full text read0.90
Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.
Finding0.16 QALYs gained with icodec versus glargine U100 and degludec.
—2026Full text read0.80
Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.
FindingHR 0.69 for 30% eGFR decline, 95% CI 0.59-0.80, p<0.001
Human2026Full text read0.80
Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Finding−0.25% HbA1c mean difference vs dulaglutide, 95% CI −0.38 to −0.12, p=0.0002
review2026Full text read0.80
Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice.
FindingNot reported in abstract.
Animal2026Full text read0.70
Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations.
Finding$6600 vs $107,992.82, yielding an ICER of -$2.25 million.
review2023Full text read0.80
Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
FindingMD = 2.73 improvement in ED score, 95% CI: 1.64-3.83
review2026Full text read0.80
Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.
FindingAdjusted mean difference for time in very low range was 0.22% (97.5% CI -0.83 to 1.27, p=0.63).
Human2023Full text read0.80
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Finding7.4% ever-use of GLP-1RAs reported in a NARCOMS survey (n=4181).
review2026Full text read0.80
A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline.
FindingIn a median of 3 (IQR 2, 4) of 1000 randomisations (0.3%), the hazard ratio for death was < 0.85 or > 1.18 by chance alone.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Dulaglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Dulaglutide is discussed should be drawn from it.